Dossier assessment
Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with unresectable or metastatic triple-negative breast cancer who have had two or more prior systemic therapies including at least one of them for advanced disease
Hint of major added benefit
Press releases
Triple-negative breast cancer: survival advantage with sacituzumab govitecan
Additional information
Federal Joint Committee (G-BA)
2022-05-20 A G-BA decision was published.
Project details
- Project no.
- A21-154
- Commission
- Commission awarded on 01.12.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Addendum
Sacituzumab govitecan (breast cancer) - Addendum to Commission A21-154
Status: Commission completed
-
Dossier assessment
Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed